Patients with severe heart failure or arrhythmias require monitoring because rapid shifts in free-fatty-acid metabolism can influence myocardial substrate utilization
Historical Role in Recovery BPC-157s healing potential was first studied in the 1990s for gastrointestinal repair, with animal trials showing accelerated tendon and muscle recovery
Injections are advised to circumvent potential absorption challenges in the gastrointestinal tract, particularly for those with known issues like Crohn's disease or irritable bowel syndrome, providing a more immediate replenishment compared to oral supplements, which may not be fully absorbed
AHK-Cu has also been studied extensively in animal models under laboratory conditions for its suggested impact on collagen synthesis
One potential downside of BPC 157 is its limited clinical testing in humans, which means long-term safety and efficacy are not well-established
Evidence note: PRP has moderate human clinical evidence